All Stories

  1. Cough in Children and Adults: Diagnosis, Assessment and Management (CICADA). Summary of an updated position statement on chronic cough in Australia
  2. Cough in Children and Adults: Diagnosis, Assessment and Management (CICADA). Summary of an updated position statement on chronic cough in Australia
  3. Large airway wall vascularity in patients with Asthma COPD overlap: a bronchoscopy study
  4. Mapping the common barriers to optimal COPD care in high and middle-income countries: qualitative perspectives from clinicians
  5. Inflammatory and antiviral responses to influenza A virus infection are dysregulated in pregnant mice with allergic airway disease
  6. Upper Respiratory Tract OC43 Infection Model for Investigating Airway Immune-modifying Therapies
  7. Mechanical forces suppress antiviral innate immune responses from asthmatic airway epithelial cells following rhinovirus infection
  8. Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist
  9. Saline at lower tonicity in CF (SALTI-CF) trial comparing 0.9% v 3% v 6% nebulised saline
  10. BILE ACIDS IN LOWER AIRWAYS AS A NOVEL INDICATOR OF AIRWAY MICROBIOTA CHANGES IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
  11. Comparative B cell and antibody responses induced by adenoviral vectored and mRNA vaccines against COVID-19
  12. Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics
  13. Comparison of commercially available differentiation media on morphology, function, and virus-host interaction in conditionally reprogrammed human bronchial epithelial cells
  14. A systematic review of the colorectal microbiome in adult cystic fibrosis patients
  15. Probiotic Bifidobacterium longum subsp. longum Protects against Cigarette Smoke-Induced Inflammation in Mice
  16. Survival of people with cystic fibrosis in Australia
  17. Conditionally reprogrammed asthmatic bronchial epithelial cells express lower FOXJ1 at terminal differentiation and lower IFNs following RV-A1 infection
  18. Obesity and COVID-19 Disease: To Inflame or Not
  19. Association between dietary fibre, microbial metabolites and airway obstruction in COPD patients and murine models
  20. Crucial role of iron metabolism in determining outcomes of influenza A virus infection and disease
  21. Histone deacetylase-6 (HDAC6) promotes protective responses during murine influenza A virus (IAV) infection
  22. Hydrogen sulfide attenuates cigarette smoke-induced oxidative stress and inflammation in human primary bronchial epithelial cells and experimental COPD
  23. Relationship between interleukin-13 and transferrin receptor-1 responses in the pathogenesis of asthma
  24. Regional variation in prevalence of difficult-to-treat asthma and oral corticosteroid use for patients in Australia: heat map analysis
  25. We need to understand why viral infections lead to acute asthma
  26. Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease
  27. IL-25 blockade augments antiviral immunity during respiratory virus infection
  28. Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2019: the Influenza Complications Alert Network FluCAN
  29. Mental health care needs in cystic fibrosis: A scoping review
  30. Understanding motivation for Australian adolescents and young adults with cystic fibrosis: Modifiable factors to support self‐management
  31. Pathogenesis, clinical features of asthma COPD overlap, and therapeutic modalities
  32. Surveillance for severe influenza and COVID-19 in patients admitted to sentinel Australian hospitals in 2020: the Influenza Complications Alert Network (FluCAN)
  33. Factors Associated with Asthma Exacerbations During Pregnancy
  34. Increased cough, mucus and wheeze characterise COPD and Asthma in Australian Aboriginal adults
  35. We are not doing enough to prevent the spread of COVID‐19 and other respiratory viruses in Australian hospitals
  36. Transcriptomics of biopsies identifies novel genes and pathways linked to neutrophilic inflammation in severe asthma
  37. Asthma, COPD and SARS-CoV-2 infection (COVID-19): potential mechanistic insights
  38. Dysregulated actin cytoskeleton associated with barrier dysfunction in asthma
  39. Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
  40. Redesign of the Australian Cystic Fibrosis Data Registry: A multidisciplinary collaboration
  41. Asthma-COPD overlap: current understanding and the utility of experimental models
  42. ACE2 expression is elevated in airway epithelial cells from older and male healthy individuals but reduced in asthma
  43. Dysregulation of endocytic machinery and ACE2 in small airways of smokers and COPD patients can augment their susceptibility to SARS-CoV-2 (COVID-19) infections
  44. Hemopexin: A Novel Anti-inflammatory Marker for Distinguishing COPD From Asthma
  45. TLR2-mediated innate immune priming boosts lung anti-viral immunity
  46. Molecular and Immunological Mechanisms Underlying the Various Pharmacological Properties of the Potent Bioflavonoid, Rutin
  47. Human coronaviruses 229E and OC43 replicate and induce distinct antiviral responses in differentiated primary human bronchial epithelial cells
  48. Curcumin-loaded niosomes downregulate mRNA expression of pro-inflammatory markers involved in asthma: an in vitro study
  49. Omalizumab Is an Effective Intervention in Severe Asthma with Fungal Sensitization
  50. Australian cystic fibrosis community views on organoids
  51. PAT in the ER for Transmembrane Protein Folding
  52. Severe Nocardia pneumonia in an immunocompromised patient with alpha‐1 antitrypsin deficiency
  53. Omalizumab is an effective intervention in severe asthma with aspergillus sensitisation
  54. Managing T2-High Inflammation in Severe Asthma - Are Biomarkers Better Than Clinician Judgement?
  55. Late Breaking Abstract - ACE2 expression in lower airway epithelial cells is increased with age and in males, but is less in asthma
  56. ACE2 Expression is elevated in Airway Epithelial Cells from aged and male donors but reduced in asthma
  57. A Sputum 6 Gene Expression Signature Predicts Inflammatory Phenotypes and Future Exacerbations of COPD
  58. Molecular mechanisms of action of naringenin in chronic airway diseases
  59. Celastrol-loaded liquid crystalline nanoparticles as an anti-inflammatory intervention for the treatment of asthma
  60. Asthma and the Dysregulated Immune Response to Rhinovirus
  61. Management of acute COPD exacerbations in Australia: do we follow the guidelines?
  62. A survey of specialist opinions on biomarker use in severe asthma in Australia: scepticism but hope?
  63. Contemporary Concise Review 2019: Asthma
  64. Diagnosis and treatment of lung disease associated with alpha one‐antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand*
  65. Immunological axis of berberine in managing inflammation underlying chronic respiratory inflammatory diseases
  66. Six gene and TH2 signature expression in endobronchial biopsies of participants with asthma
  67. Sputum transcriptomics implicates increased p38 signalling activity in severe asthma
  68. Targeting treatable traits in severe asthma: a randomised controlled trial
  69. Antiviral immunity is impaired in COPD patients with frequent exacerbations
  70. Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease
  71. Preparation, characterization and in-vitro efficacy of quercetin loaded liquid crystalline nanoparticles for the treatment of asthma
  72. Nasal epithelial cells to assess in vitro immune responses to respiratory virus infection in pregnant women with asthma
  73. Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2018: the Influenza Complications Alert Network (FluCAN)
  74. Blood Neutrophils In COPD But Not Asthma Exhibit A Primed Phenotype With Downregulated CD62L Expression
  75. Hypoxia‐inducible factor and bacterial infections in chronic obstructive pulmonary disease
  76. People with asthma are more likely to become ill from influenza
  77. A multicentre, observational cohort study to determine the efficacy and safety of lumacaftor/ivacaftor in patients with severe lung disease and cystic fibrosis
  78. Asthmatic airway epithelial cells subjected to apical mechanical stress exhibit suppressed interferon release following viral infection
  79. Circulatory neutrophils in COPD feature downregulated CD62L expression in comparison with asthma and healthy participants
  80. Inhibition of ER stress suppresses IL-13 induced airway epithelial remodeling
  81. Endobronchial biopsy gene expression between different severe asthma inflammatory phenotypes
  82. Treatment with Omalizumab in adults with severe allergic reduces Fc?I expression on dendritic cells and improves antiviral responses
  83. Sputum gene signature comparison study between U-BIOPRED and Australia asthma cohorts
  84. Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2017: the Influenza Complications Alert Network (FluCAN)
  85. Fibulin-1c regulates transforming growth factor–β activation in pulmonary tissue fibrosis
  86. RIPLET, and not TRIM25, is required for endogenous RIG‐I‐dependent antiviral responses
  87. Respiratory syncytial virus co-opts host mitochondrial function to favour infectious virus production
  88. Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction
  89. IL-22 and its receptors are increased in human and experimental COPD and contribute to pathogenesis
  90. Platelet activating factor receptor regulates colitis-induced pulmonary inflammation through the NLRP3 inflammasome
  91. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report
  92. The importance of acute asthma.
  93. CSF3R/CD114 mediates infection-dependent transition to severe asthma
  94. Hypersegmented airway neutrophils and its association with reduced lung function in adults with obstructive airway disease: an exploratory study
  95. Molecular modulators of celastrol as the keystones for its diverse pharmacological activities
  96. Enhancing tristetraprolin activity reduces the severity of cigarette smoke‐induced experimental chronic obstructive pulmonary disease
  97. The interplay of the host, virus, and the environment
  98. Assessing the potential of liposomes loaded with curcumin as a therapeutic intervention in asthma
  99. Multi-Centre Ethics and Research Governance Review Can Impede Non-Interventional Clinical Research
  100. Roles for T/B lymphocytes and ILC2s in experimental chronic obstructive pulmonary disease
  101. Nebulised hypertonic saline for cystic fibrosis
  102. Treatable traits can be identified in a severe asthma registry and predict future exacerbations
  103. Mechanisms of impaired anti-bacterial Th1 responses in patients with chronic obstructive pulmonary disease
  104. Identification of treatable traits in a severe asthma registry: prevalence and exacerbation predictors
  105. Influenza Epidemiology, Vaccine Coverage and Vaccine Effectiveness in Children Admitted to Sentinel Australian Hospitals in 2017: Results from the PAEDS-FluCAN Collaboration
  106. Influenza A virus infection dysregulates the expression of microRNA-22 and its targets; CD147 and HDAC4, in epithelium of asthmatics
  107. Appropriate use of oral corticosteroids for severe asthma
  108. Effects of fruit and vegetable consumption on inflammatory biomarkers and immune cell populations: a systematic literature review and meta-analysis
  109. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations
  110. Trends in asthma self-management skills and inhaled corticosteroid use during pregnancy and postpartum from 2004 to 2017
  111. Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches
  112. Developments in cystic fibrosis personalised epithelial assays: Science and patient perspectives
  113. Pseudomonas pharyngitis in a cystic fibrosis patient
  114. Immunological axis of curcumin-loaded vesicular drug delivery systems
  115. Impaired Th1 responses in patients with acute exacerbations of COPD are improved with PD-1 blockade
  116. Understanding the Unfolded Protein Response in the Pathogenesis of Asthma
  117. Respiratory Viruses and Asthma
  118. Eosinophilia as a treatable trait in three patients with asthma and COPD
  119. Pathophysiology of severe asthma: We’ve only just started
  120. Systematic review and website presentation of validated dietary assessment tools
  121. Airway remodelling and inflammation in asthma are dependent on the extracellular matrix protein fibulin-1c
  122. ENHANCED CD147 EXPRESSION AFTER H1N1 INFECTION; A POTENTIAL MECHANISM FOR AIRWAY EPITHELIUM IMPAIRMENT IN ASTHMA
  123. SPUTUM 6 GENE EXPRESSION SIGNATURE PREDICTS INFLAMMATORY PHENOTYPE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  124. A new website to support dietary assessment in health research: Nutritools.org
  125. Treatment burden, clinical outcomes, and comorbidities in COPD: an examination of the utility of medication regimen complexity index in COPD
  126. Multidimensional assessment and targeted therapy of severe asthma: a randomised controlled trial (RCT)
  127. A transcriptomic comparison between nasal and bronchial airway epithelia from children
  128. Regulation of xanthine dehydrogensase gene expression and uric acid production in human airway epithelial cells
  129. Role for NLRP3 Inflammasome–mediated, IL-1β–Dependent Responses in Severe, Steroid-Resistant Asthma
  130. MicroRNA-125a and -b inhibit A20 and MAVS to promote inflammation and impair antiviral response in COPD
  131. Effects of Fruit and Vegetable Consumption on Risk of Asthma, Wheezing and Immune Responses: A Systematic Review and Meta-Analysis
  132. Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signaling
  133. Role of miR-218 in COPD
  134. Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)
  135. Use of biologics to treat acute exacerbations and manage disease in asthma, COPD and IPF
  136. Severe asthma: Current management, targeted therapies and future directions-A roundtable report
  137. Acute myocardial infarction in disseminated mucormycosis infection
  138. The genetic and epigenetic landscapes of the epithelium in asthma
  139. A treatment algorithm adjusting oral corticosteroid using blood eosinophils reduces exacerbations and improves asthma control, in difficult asthmatics
  140. Effect of oxidative stress and rhinovirus infection on mitochondrial/endoplasmic reticular function in human primary bronchial epithelial cells
  141. Micro-RNA-125a/b target A20 and MAVS to promote inflammatory and impair antiviral responses in chronic obstructive pulmonary disease
  142. NLRP3 inflammasome-mediated, IL-1β-dependent inflammatory responses drive steroid-resistant asthma
  143. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry
  144. Recent advances in understanding and managing asthma
  145. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD
  146. Impaired Antiviral Stress Granule and IFN-β Enhanceosome Formation Enhances Susceptibility to Influenza Infection in Chronic Obstructive Pulmonary Disease Epithelium
  147. What is asthma−COPD overlap syndrome? Towards a consensus definition from a round table discussion
  148. Fibulin-1 regulates the pathogenesis of tissue remodeling in respiratory diseases
  149. Advances in the treatment of virus-induced asthma
  150. Acute oxygen therapy: a review of prescribing and delivery practices
  151. Targeted therapeutics for severe refractory asthma: monoclonal antibodies
  152. Diagnosis and investigation in the severe asthma clinic
  153. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis
  154. Innate Immunity and Immune Evasion by Enterovirus 71
  155. Influenza vaccine effectiveness against hospitalisation with influenza in adults in Australia in 2014
  156. A pathogenic role for tumor necrosis factor-related apoptosis-inducing ligand in chronic obstructive pulmonary disease
  157. Can blood eosinophils predict sputum eosinophils in stable COPD?
  158. Potential role of SPARC, a downstream mediator of TGF-b in chronic airways disease
  159. Adjusting prednisone using blood eosinophils reduces exacerbations and improves asthma control in difficult patients with asthma
  160. The social network of cystic fibrosis centre care and shared Pseudomonas aeruginosa strain infection: a cross-sectional analysis
  161. Toll-like receptor 7 governs interferon and inflammatory responses to rhinovirus and is suppressed by IL-5-induced lung eosinophilia
  162. Targeting PI3K-p110α Suppresses Influenza Virus Infection in Chronic Obstructive Pulmonary Disease
  163. The Placental Protein Syncytin-1 Impairs Antiviral Responses and Exaggerates Inflammatory Responses to Influenza
  164. CD8 T cells and dendritic cells: key players in the attenuated maternal immune response to influenza infection
  165. World alliance against antibiotic resistance: The WAAAR declaration against antibiotic resistance
  166. Airwayβ-Defensin-1 Protein Is Elevated in COPD and Severe Asthma
  167. 81
  168. 82
  169. 175
  170. 147
  171. Differential injurious effects of ambient and traffic-derived particulate matter on airway epithelial cells
  172. How the placenta makes pregnant women vulnerable to influenza (Flu)
  173. PP38 Development of a new UK food composition database
  174. The Effect of Inhaled IFN-β on Worsening of Asthma Symptoms Caused by Viral Infections. A Randomized Trial
  175. Cough Formation in Viral Infections in Children
  176. The interaction between mother and fetus and the development of allergic asthma
  177. TLR3 and MDA5 signalling, although not expression, is impaired in asthmatic epithelial cells in response to rhinovirus infection.
  178. A Prospective Study of Respiratory Viral Infection in Pregnant Women With and Without Asthma
  179. Viral and bacterial infection in acute asthma and chronic obstructive pulmonary disease increases the risk of readmission
  180. Influenza Vaccine Effectiveness against Hospitalisation with Confirmed Influenza in the 2010–11 Seasons: A Test-negative Observational Study
  181. Plasmacytoid Dendritic Cells and CD8 T Cells From Pregnant Women Show Altered Phenotype and Function Following H1N1/09 Infection
  182. Alterations in inflammatory, antiviral and regulatory cytokine responses in peripheral blood mononuclear cells from pregnant women with asthma
  183. Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease
  184. A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis
  185. The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity
  186. Novel immune genes associated with excessive inflammatory and antiviral responses to rhinovirus in COPD
  187. Deficient antiviral responses to influenza in primary bronchial epithelial cells of chronic obstructive pulmonary disease
  188. Innate immunity to influenza in chronic airways diseases
  189. RAGE: a new frontier in chronic airways disease
  190. SharedPseudomonas aeruginosagenotypes are common in Australian cystic fibrosis centres
  191. Viral infections trigger exacerbations of cystic fibrosis in adults and children: Figure 1–
  192. Pregnant Women Have Attenuated Innate Interferon Responses to 2009 Pandemic Influenza A Virus Subtype H1N1
  193. Characteristics of a Widespread Community Cluster of H275Y Oseltamivir-Resistant A(H1N1)pdm09 Influenza in Australia
  194. Multicentre audit of inpatient management of acute exacerbations of chronic obstructive pulmonary disease: comparison with clinical guidelines
  195. Airway inflammation in asthma, a single measurement is not enough
  196. Glucocorticosteroids Differentially Regulate MMP-9 and Neutrophil Elastase in COPD
  197. Critical Role of Constitutive Type I Interferon Response in Bronchial Epithelial Cell to Influenza Infection
  198. Serum amyloid A opposes lipoxin A 4 to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease
  199. Clinical and physiological features of postinfectious chronic cough associated with H1N1 infection
  200. Developments in the field of allergy in 2010 through the eyes of Clinical and Experimental Allergy
  201. Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: A test-negative case control study
  202. Soluble RAGE is deficient in neutrophilic asthma and COPD
  203. Impaired type I and III interferon response to rhinovirus infection during pregnancy and asthma
  204. P2-316 Adult height in relation to cancer mortality in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort
  205. Tiotropium reduced exacerbations more than salmeterol in moderate-to-very severe COPD
  206. Human Influenza Is More Effective than Avian Influenza at Antiviral Suppression in Airway Cells
  207. A Novel E3 Ubiquitin Ligase Links Rhinovirus Infection To Exacerbation Of Asthma
  208. Respiratory Examination
  209. Characterization of innate immune signalling receptors in virus-induced acute asthma
  210. Antioxidant and Anti-Inflammatory Effects of Resveratrol in Airway Disease
  211. Down-titration from high-dose combination therapy in asthma: Removal of long-acting β2-agonist
  212. Viral and bacterial interactions in pneumonia
  213. TLR5 is not required for flagellin-mediated exacerbation of DSS colitis
  214. Asthma during pregnancy alters immune cell profile and airway epithelial chemokine release
  215. Lycopene enrichment of cultured airway epithelial cells decreases the inflammation induced by rhinovirus infection and lipopolysaccharide
  216. Nebulised hypertonic saline for cystic fibrosis
  217. Low Rates of Pseudomonas aeruginosa Misidentification in Isolates from Cystic Fibrosis Patients
  218. Diversity in the bronchial epithelial cell response to infection with different rhinovirus strains
  219. Pathogenesis of ABPA
  220. Guest Editorial
  221. Innate immune response to viral infection of the lungs
  222. Flagellin exacerbates DSS induced Colitis via TLR5 independent mechanisms
  223. SUPPLEMENTATION OF LONG CHAIN N-3 POLYUNSATURATED FATTY ACIDS INCREASES THE UTILIZATION OF LYCOPENE IN CULTURED AIRWAY EPITHELIAL CELLS
  224. Anti-inflammatory effects of long-chain n-3 PUFA in rhinovirus-infected cultured airway epithelial cells
  225. Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii
  226. Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages
  227. The role of exhaled nitric oxide and exhaled breath condensates in evaluating airway inflammation in asthma
  228. Understanding the mechanisms of viral induced asthma: New therapeutic directions
  229. Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease
  230. IFN-γ–induced protein 10 is a novel biomarker of rhinovirus-induced asthma exacerbations
  231. Asthma exacerbations {middle dot} 3: Pathogenesis
  232. Role of deficient type III interferon-λ production in asthma exacerbations
  233. Nebulised hypertonic saline for cystic fibrosis
  234. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus
  235. Induced Sputum 8-Isoprostane Concentrations in Inflammatory Airway Diseases
  236. Pathogenesis of allergic bronchopulmonary aspergillosis and an evidence-based review of azoles in treatment
  237. Hyperkalaemic ascending paralysis
  238. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: A randomized controlled trial
  239. Use of induced sputum for the diagnosis of influenza and infections in asthma: a comparison of diagnostic techniques
  240. Airway inflammation in thunderstorm asthma
  241. Chlamydia pneumoniae immunoglobulin A reactivation and airway inflammation in acute asthma
  242. Optimization of sputum-processing methods for the measurement of interleukin-5: Effects of protease inhibition
  243. Non-invasive ventilation in acute respiratory failure
  244. Safety of sputum induction with isotonic saline in adults with acute severe asthma
  245. Allergic bronchopulmonary aspergillosis: New concepts of pathogenesis and treatment
  246. Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma
  247. Induced sputum eosinophils and neutrophils and bronchiectasis severity in allergic bronchopulmonary aspergillosis
  248. Induced sputum eosinophils in the assessment of asthma and chronic cough*
  249. Bronchitis
  250. Difficult Asthma
  251. Non-Invasive Ventilation in Acute Respiratory Failure